• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Advances in the study of biomarkers related to bone metastasis in breast cancer.乳腺癌骨转移相关生物标志物研究进展。
Br J Radiol. 2023 Oct;96(1150):20230117. doi: 10.1259/bjr.20230117. Epub 2023 Jul 3.
2
Interleukins as Mediators of the Tumor Cell-Bone Cell Crosstalk during the Initiation of Breast Cancer Bone Metastasis.白细胞介素作为乳腺癌骨转移起始过程中肿瘤细胞与骨细胞串扰的介质。
Int J Mol Sci. 2021 Mar 12;22(6):2898. doi: 10.3390/ijms22062898.
3
Identification and validation of DOCK4 as a potential biomarker for risk of bone metastasis development in patients with early breast cancer.鉴定和验证 DOCK4 作为早期乳腺癌患者骨转移发展风险的潜在生物标志物。
J Pathol. 2019 Mar;247(3):381-391. doi: 10.1002/path.5197. Epub 2019 Jan 25.
4
OLFM4, LY6D and S100A7 as potent markers for distant metastasis in estrogen receptor-positive breast carcinoma.OLFM4、LY6D 和 S100A7 是雌激素受体阳性乳腺癌远处转移的有效标志物。
Cancer Sci. 2018 Oct;109(10):3350-3359. doi: 10.1111/cas.13770. Epub 2018 Sep 27.
5
1α,25-Dihydroxyvitamin D Inhibits the Metastatic Capability of MCF10CA1a and MDA-MB-231 Cells in an In Vitro Model of Breast to Bone Metastasis.1α,25-二羟基维生素D在乳腺癌向骨转移的体外模型中抑制MCF10CA1a和MDA-MB-231细胞的转移能力。
Nutr Cancer. 2016 Oct;68(7):1202-9. doi: 10.1080/01635581.2016.1213868. Epub 2016 Aug 23.
6
MicroRNA expression as risk biomarker of breast cancer metastasis: a pilot retrospective case-cohort study.微小RNA表达作为乳腺癌转移的风险生物标志物:一项前瞻性回顾性病例队列研究。
BMC Cancer. 2014 Oct 2;14:739. doi: 10.1186/1471-2407-14-739.
7
MicroRNAs and Their Roles in Breast Cancer Bone Metastasis.微小 RNA 及其在乳腺癌骨转移中的作用。
Curr Osteoporos Rep. 2021 Jun;19(3):256-263. doi: 10.1007/s11914-021-00677-9. Epub 2021 Apr 8.
8
A mandatory role of nuclear PAK4-LIFR axis in breast-to-bone metastasis of ERα-positive breast cancer cells.核 PAK4-LIFR 轴在 ERα 阳性乳腺癌细胞骨转移中的强制性作用。
Oncogene. 2019 Feb;38(6):808-821. doi: 10.1038/s41388-018-0456-0. Epub 2018 Sep 3.
9
Immunohistochemistry analysis of autophagy-related proteins Beclin-1, p62/SQSTM1, and LC3B in breast carcinoma progression to bone metastasis.乳腺癌骨转移进程中自噬相关蛋白 Beclin-1、p62/SQSTM1 和 LC3B 的免疫组化分析。
Pathol Res Pract. 2024 Aug;260:155414. doi: 10.1016/j.prp.2024.155414. Epub 2024 Jun 17.
10
Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer.血清骨膜蛋白水平在乳腺癌而非肺癌骨转移患者中升高。
Breast Cancer Res Treat. 2003 Feb;77(3):245-52. doi: 10.1023/a:1021899904332.

引用本文的文献

1
Stabilization of Symptomatic Bone Marrow Metastases in Breast Cancer: A Case Report of Two Patients Treated With Trastuzumab Deruxtecan.曲妥珠单抗德鲁昔单抗治疗乳腺癌有症状骨髓转移的病情稳定:两例患者的病例报告
Cureus. 2025 Jul 1;17(7):e87118. doi: 10.7759/cureus.87118. eCollection 2025 Jul.
2
Biomarker-Driven Approaches to Bone Metastases: From Molecular Mechanisms to Clinical Applications.生物标志物驱动的骨转移治疗方法:从分子机制到临床应用
Biomedicines. 2025 May 10;13(5):1160. doi: 10.3390/biomedicines13051160.
3
Case report: Single patellar metastasis of breast cancer.病例报告:乳腺癌单发性髌骨转移
Front Endocrinol (Lausanne). 2025 Mar 27;16:1488216. doi: 10.3389/fendo.2025.1488216. eCollection 2025.
4
Cancer metastasis: molecular mechanisms and therapeutic interventions.癌症转移:分子机制与治疗干预
Mol Biomed. 2025 Apr 7;6(1):20. doi: 10.1186/s43556-025-00261-y.
5
Standardization of a Model of Vertebral Metastasis of Breast Cancer in CD1/Nu/Nu Mice.CD1/Nu/Nu小鼠乳腺癌椎体转移模型的标准化
Cureus. 2025 Jan 11;17(1):e77291. doi: 10.7759/cureus.77291. eCollection 2025 Jan.
6
In Silico Discovery of Stapled Peptide Inhibitor Targeting the Nur77-PPARγ Interaction and Its Anti-Breast-Cancer Efficacy.基于 Nur77-PPARγ 相互作用的嵌合肽抑制剂的计算机虚拟筛选及其抗乳腺癌活性
Adv Sci (Weinh). 2024 Jul;11(26):e2308435. doi: 10.1002/advs.202308435. Epub 2024 Apr 29.

乳腺癌骨转移相关生物标志物研究进展。

Advances in the study of biomarkers related to bone metastasis in breast cancer.

机构信息

Department of Spine Surgery and Orthopaedics, Xiangya Hospital, Central South University, Changsha, China.

National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.

出版信息

Br J Radiol. 2023 Oct;96(1150):20230117. doi: 10.1259/bjr.20230117. Epub 2023 Jul 3.

DOI:10.1259/bjr.20230117
PMID:37393528
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10546430/
Abstract

Breast cancer is by far the most common malignancy in females. And bone is the most common site of distant metastasis in breast cancer, accounting for about 65 to 75% of all metastatic breast cancer patients.Bone metastasis is an important factor affecting the prognosis of breast cancer. When patients have early-stage breast cancer without metastasis, their 5-year survival rate is as high as 90%, and once metastasis occurs, their 5-year survival rate will drop to 10%. Bone radionuclide imaging (ECT), X-ray, CT scan, MRI and other imaging tests to diagnose breast cancer bone metastasis are commonly used in clinical, It is currently believed that breast cancer bone metastasis is a multistep process: first, breast cancer cells need to acquire invasive and metastatic properties; breast cancer cells enter the blood circulation and migrate from blood breast cancer cells enter the blood circulation and migrate from blood vessels to bone tissue in a targeted manner; breast cancer cells adhere and remain in bone tissue and colonise it; and finally, it leads to bone destruction. Several key molecules are involved in breast cancer bone metastasis, and serum biomarkers are generally able to detect pathological changes earlier Several key molecules are involved in breast cancer bone metastasis, and serum biomarkers are generally able to detect pathological changes earlier than imaging. This review describes the progress of serum biomarkers for breast cancer bone metastasis.

摘要

乳腺癌是女性最常见的恶性肿瘤。骨骼是乳腺癌远处转移最常见的部位,约占所有转移性乳腺癌患者的 65%至 75%。骨转移是影响乳腺癌预后的重要因素。当患者患有无转移的早期乳腺癌时,其 5 年生存率高达 90%,一旦发生转移,其 5 年生存率将下降至 10%。核素骨显像(ECT)、X 线、CT 扫描、MRI 等影像学检查常用于临床诊断乳腺癌骨转移,目前认为乳腺癌骨转移是一个多步骤的过程:首先,乳腺癌细胞需要获得侵袭性和转移性特性;乳腺癌细胞进入血液循环并从血管中定向迁移到骨组织;乳腺癌细胞黏附和定植于骨组织并殖民化;最后,导致骨破坏。乳腺癌骨转移涉及几个关键分子,而血清标志物通常能够比影像学更早地检测到病理变化。本文综述了乳腺癌骨转移的血清标志物的研究进展。